Metabolic dysfunction: The silenced connection with fatty liver disease
Ann Hepatol. 2023 Jul 17:101138. doi: 10.1016/j.aohep.2023.101138. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) represents a global public health burden. Despite the increase in its prevalence, the disease has not received sufficient attention compared to the associated diseases such as diabetes mellitus and obesity. In 2020 it was proposed to rename NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) in order to recognize the metabolic risk factors and the complex pathophysiological mechanisms associated with its development. Furthermore, along with the implementation of the pr...
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Mariana M Ram írez-Mejía Xingshun Qi Ludovico Abenavoli Manuel Romero-G ómez Mohammed Eslam Nahum M éndez-Sánchez Source Type: research
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: what's new 12 months later?
CONCLUSIONS: Disruption of routine healthcare services because of the pandemic translated to reduced 1 year overall and disease-free survival among patients affected by HCC, in the metropolitan area of Paris, France.PMID:37468096 | DOI:10.1016/j.aohep.2023.101141 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Raffaele Brustia Mohamed Bouattour Manon Allaire Marie Lequoy Cl émence Hollande H élène Regnault Lorraine Blaise Nathalie Ganne-Carri é Val érie Vilgrain Edouard Larrey Chetana Lim Olivier Scatton Sanaa El Mouhadi Violaine Ozenne Fran çois Paye Pie Source Type: research
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
CONCLUSIONS: The observation of a lower LSM in people taking SGLT2i and/or GLP-1a following adjustment for other relevant clinico-demographic variables provides support for clinical trials to assess their efficacy in reducing the progression of NAFLD.PMID:37468097 | DOI:10.1016/j.aohep.2023.101142 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Lucy Gracen Withma Muthukumara Melanie Aikebuse Anthony Russell James O'Beirne Katharine M Irvine Suzanne Williams Gaurav Puri Patricia C Valery Kelly L Hayward Elizabeth E Powell Source Type: research
Metabolic dysfunction: The silenced connection with fatty liver disease
Ann Hepatol. 2023 Jul 17:101138. doi: 10.1016/j.aohep.2023.101138. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) represents a global public health burden. Despite the increase in its prevalence, the disease has not received sufficient attention compared to the associated diseases such as diabetes mellitus and obesity. In 2020 it was proposed to rename NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) in order to recognize the metabolic risk factors and the complex pathophysiological mechanisms associated with its development. Furthermore, along with the implementation of the pr...
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Mariana M Ram írez-Mejía Xingshun Qi Ludovico Abenavoli Manuel Romero-G ómez Mohammed Eslam Nahum M éndez-Sánchez Source Type: research
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: what's new 12 months later?
CONCLUSIONS: Disruption of routine healthcare services because of the pandemic translated to reduced 1 year overall and disease-free survival among patients affected by HCC, in the metropolitan area of Paris, France.PMID:37468096 | DOI:10.1016/j.aohep.2023.101141 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Raffaele Brustia Mohamed Bouattour Manon Allaire Marie Lequoy Cl émence Hollande H élène Regnault Lorraine Blaise Nathalie Ganne-Carri é Val érie Vilgrain Edouard Larrey Chetana Lim Olivier Scatton Sanaa El Mouhadi Violaine Ozenne Fran çois Paye Pie Source Type: research
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
CONCLUSIONS: The observation of a lower LSM in people taking SGLT2i and/or GLP-1a following adjustment for other relevant clinico-demographic variables provides support for clinical trials to assess their efficacy in reducing the progression of NAFLD.PMID:37468097 | DOI:10.1016/j.aohep.2023.101142 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Lucy Gracen Withma Muthukumara Melanie Aikebuse Anthony Russell James O'Beirne Katharine M Irvine Suzanne Williams Gaurav Puri Patricia C Valery Kelly L Hayward Elizabeth E Powell Source Type: research
Metabolic dysfunction: The silenced connection with fatty liver disease
Ann Hepatol. 2023 Jul 17:101138. doi: 10.1016/j.aohep.2023.101138. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) represents a global public health burden. Despite the increase in its prevalence, the disease has not received sufficient attention compared to the associated diseases such as diabetes mellitus and obesity. In 2020 it was proposed to rename NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) in order to recognize the metabolic risk factors and the complex pathophysiological mechanisms associated with its development. Furthermore, along with the implementation of the pr...
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Mariana M Ram írez-Mejía Xingshun Qi Ludovico Abenavoli Manuel Romero-G ómez Mohammed Eslam Nahum M éndez-Sánchez Source Type: research
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: what's new 12 months later?
CONCLUSIONS: Disruption of routine healthcare services because of the pandemic translated to reduced 1 year overall and disease-free survival among patients affected by HCC, in the metropolitan area of Paris, France.PMID:37468096 | DOI:10.1016/j.aohep.2023.101141 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Raffaele Brustia Mohamed Bouattour Manon Allaire Marie Lequoy Cl émence Hollande H élène Regnault Lorraine Blaise Nathalie Ganne-Carri é Val érie Vilgrain Edouard Larrey Chetana Lim Olivier Scatton Sanaa El Mouhadi Violaine Ozenne Fran çois Paye Pie Source Type: research
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
CONCLUSIONS: The observation of a lower LSM in people taking SGLT2i and/or GLP-1a following adjustment for other relevant clinico-demographic variables provides support for clinical trials to assess their efficacy in reducing the progression of NAFLD.PMID:37468097 | DOI:10.1016/j.aohep.2023.101142 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Lucy Gracen Withma Muthukumara Melanie Aikebuse Anthony Russell James O'Beirne Katharine M Irvine Suzanne Williams Gaurav Puri Patricia C Valery Kelly L Hayward Elizabeth E Powell Source Type: research
Metformin ameliorates liver fibrosis induced by congestive hepatopathy via the mTOR/HIF-1 α signaling pathway
CONCLUSIONS: Metformin inhibits CH-induced liver fibrosis. Functionally, this beneficial effect may be the result of inhibition of HSC activation and of the mTOR/HIF-1α signaling pathway.PMID:37451514 | DOI:10.1016/j.aohep.2023.101135 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 14, 2023 Category: Gastroenterology Authors: Jing Yang Suxin Li Shengyan Liu Yuehui Zhang Dongqi Shen Peiju Wang Xiaowei Dang Source Type: research
Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma
Ann Hepatol. 2023 Jul 13:101137. doi: 10.1016/j.aohep.2023.101137. Online ahead of print.ABSTRACTMost cases of hepatocellular carcinoma (HCC) are able to be diagnosed through regular surveillance in an identifiable patient population with chronic hepatitis B or cirrhosis. Nevertheless, 50% of global cases might present incidentally owing to symptomatic advanced-stage HCC after worsening of liver dysfunction. A systematic search based on PUBMED was performed to identify relevant outcomes, covering newer surveillance modalities including secretory proteins, DNA methylation, miRNAs, and genome sequencing analysis which propos...
Source: Annals of Hepatology - July 14, 2023 Category: Gastroenterology Authors: Miner Hu Xiaojun Xia Lichao Chen Yunpeng Jin Zhenhua Hu Shudong Xia Xudong Yao Source Type: research
Metformin ameliorates liver fibrosis induced by congestive hepatopathy via the mTOR/HIF-1 α signaling pathway
CONCLUSIONS: Metformin inhibits CH-induced liver fibrosis. Functionally, this beneficial effect may be the result of inhibition of HSC activation and of the mTOR/HIF-1α signaling pathway.PMID:37451514 | DOI:10.1016/j.aohep.2023.101135 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 14, 2023 Category: Gastroenterology Authors: Jing Yang Suxin Li Shengyan Liu Yuehui Zhang Dongqi Shen Peiju Wang Xiaowei Dang Source Type: research
Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma
Ann Hepatol. 2023 Jul 13:101137. doi: 10.1016/j.aohep.2023.101137. Online ahead of print.ABSTRACTMost cases of hepatocellular carcinoma (HCC) are able to be diagnosed through regular surveillance in an identifiable patient population with chronic hepatitis B or cirrhosis. Nevertheless, 50% of global cases might present incidentally owing to symptomatic advanced-stage HCC after worsening of liver dysfunction. A systematic search based on PUBMED was performed to identify relevant outcomes, covering newer surveillance modalities including secretory proteins, DNA methylation, miRNAs, and genome sequencing analysis which propos...
Source: Annals of Hepatology - July 14, 2023 Category: Gastroenterology Authors: Miner Hu Xiaojun Xia Lichao Chen Yunpeng Jin Zhenhua Hu Shudong Xia Xudong Yao Source Type: research
Metformin ameliorates liver fibrosis induced by congestive hepatopathy via the mTOR/HIF-1 α signaling pathway
CONCLUSIONS: Metformin inhibits CH-induced liver fibrosis. Functionally, this beneficial effect may be the result of inhibition of HSC activation and of the mTOR/HIF-1α signaling pathway.PMID:37451514 | DOI:10.1016/j.aohep.2023.101135 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 14, 2023 Category: Gastroenterology Authors: Jing Yang Suxin Li Shengyan Liu Yuehui Zhang Dongqi Shen Peiju Wang Xiaowei Dang Source Type: research
